Semaglutide Patent Expiry in India: Affordable Weight-Loss Injections Set to Cost ₹3,000–4,000 Per Month from March 21
The long-awaited patent cliff for semaglutide, the active ingredient in blockbuster drugs like Ozempic and Wegovy, has arrived in India. Novo Nordisk’s key Indian patent on the molecule expired on March 20, 2026, paving the way for a flood of generic and branded-generic versions starting March 21. This development is expected to dramatically improve access to the popular GLP-1 receptor agonist, which is used for managing type 2 diabetes and promoting significant weight loss.
Sharp Price Reduction Expected
Branded semaglutide injections have been prohibitively expensive for many patients. Current monthly costs for Ozempic typically range from approximately ₹8,800 to ₹11,175, depending on the dose (0.25 mg, 0.5 mg, or 1 mg pens), while Wegovy has been priced even higher, often between ₹10,000 and ₹16,400 per month.
With the entry of generics, prices are projected to fall sharply — to around ₹3,000–4,000 per month in the initial phase for once-weekly injections. Some estimates suggest costs could eventually drop further to ₹1,500–2,500 or even lower as competition intensifies, representing a reduction of 50–70% or more from branded versions. Manufacturing analyses indicate the drug could theoretically be produced for as little as a few dollars per month in high volumes.
Surge of Generic Launches
Industry experts anticipate over 50 branded-generic versions entering the market in the coming weeks and months. Major Indian pharmaceutical companies preparing launches include:
- Sun Pharma
- Dr. Reddy’s Laboratories
- Zydus Lifesciences
- Lupin
- Alkem Laboratories
- Mankind Pharma
- Cipla
- Torrent Pharmaceuticals
- Natco Pharma
- Others such as Ajanta Pharma
Several firms have already secured regulatory approvals and plan to roll out products almost immediately after the expiry. Some, like Zydus, are introducing innovative formats such as adjustable-dose reusable pens to further enhance affordability and convenience.
A Boon for Diabetes and Obesity Care in India
India bears one of the world’s highest burdens of type 2 diabetes, with over 100 million affected individuals, alongside rapidly rising obesity rates. Until now, high prices limited the reach of semaglutide-based therapies. The influx of affordable generics is expected to expand the GLP-1 market significantly — from around ₹10 billion currently to potentially ₹50 billion by 2030.
Semaglutide works by mimicking a gut hormone to regulate blood sugar, suppress appetite, and aid weight loss when combined with diet and exercise. However, experts stress that these are prescription-only medications and must be used under medical supervision. Potential side effects include gastrointestinal issues, and there are concerns about misuse for cosmetic weight loss, counterfeit products, muscle loss with prolonged use, and the importance of sustainable lifestyle changes.
Global Perspective
While India benefits from this early patent expiry, protection for semaglutide remains in place in major markets like the United States (until around 2031–2032) and Europe. Indian manufacturers may also explore export opportunities to other countries where patents are lapsing or absent, potentially influencing global supply and pricing over time.
This “patent cliff” marks a classic example of India’s robust generic pharmaceutical industry driving down costs for essential medicines. Patients and doctors alike are watching closely as the first generic semaglutide products hit pharmacies in the days ahead. Those interested in these treatments should consult a qualified healthcare professional to determine suitability and ensure safe use.
Prices and exact launch timelines may vary by brand, dose, and manufacturer as the market evolves rapidly in the coming weeks.
About The Author
